| | | | | | | | | | | | | | | | |
| |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| 2024 | 2022 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | | | DNK | R01AI135721 | A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | 000 | 5 | NIH | 7/18/2024 | $0 |
|
 | Issue Date FY: 2022 ( Subtotal = $647,855 ) |
| 2022 | 2022 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | | | DNK | R01AI135721 | A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | 000 | 5 | NIH | 12/3/2021 | $647,855 |
|
 | Issue Date FY: 2021 ( Subtotal = $1,155,591 ) |
| 2021 | 2021 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | | | DNK | R01AI135721 | A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | 001 | 4 | NIH | 1/29/2021 | $428,187 |
| 2021 | 2021 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | | | DNK | R01AI135721 | A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | 001 | 4 | NIH | 1/29/2021 | $727,404 |
| 2021 | 2020 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | | | DNK | R01AI135721 | A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | 000 | 3 | NIH | 10/22/2020 | $0 |
| 2021 | 2020 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | | | DNK | R01AI135721 | A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | 000 | 3 | NIH | 10/22/2020 | $0 |
|
 | Issue Date FY: 2020 ( Subtotal = $765,521 ) |
| 2020 | 2020 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | 2300 | | DNK | R01AI135721 | A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | 001 | 3 | NIH | 9/14/2020 | $94,907 |
| 2020 | 2020 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | 2300 | | DNK | R01AI135721 | A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | 000 | 3 | NIH | 12/2/2019 | $670,614 |
|
 | Issue Date FY: 2019 ( Subtotal = $642,131 ) |
| 2019 | 2019 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | 2300 | | DNK | R01AI135721 | A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | 000 | 2 | NIH | 11/26/2018 | $642,131 |
|
 | Issue Date FY: 2018 ( Subtotal = $277,002 ) |
| 2018 | 2018 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | 2300 | | DNK | R01AI135721 | A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | 000 | 1 | NIH | 11/27/2017 | $277,002 |
|
 | Issue Date FY: 2017 ( Subtotal = -$1 ) |
| 2017 | 2015 | STATENS SERUM INSTITUT | ARTILLERIVEJ 5 | KOBENHAVN S | | 2300 | | DNK | R01AI093697 | Genome-wide association study of febrile seizures following measles, mumps, rubel | 000 | 4 | NIH | 11/2/2016 | -$1 |
|
 | Issue Date FY: 2015 ( Subtotal = $92,703 ) |
| 2015 | 2015 | STATENS SERUM INSTITUTE | ORESTADS BOULEVARD 5 | COPENHAGEN | | | | DNK | R01AI093697 | Genome-wide association study of febrile seizures following measles, mumps, rubel | 000 | 4 | NIH | 6/15/2015 | $92,703 |
|
 | Issue Date FY: 2014 ( Subtotal = $193,478 ) |
| 2014 | 2014 | STATENS SERUM INSTITUTE | ORESTADS BOULEVARD 5 | COPENHAGEN | | | | DNK | R01AI093697 | Genome-wide association study of febrile seizures following measles, mumps, rubel | 000 | 3 | NIH | 6/24/2014 | $193,478 |
|
 | Issue Date FY: 2013 ( Subtotal = $188,951 ) |
| 2013 | 2013 | STATENS SERUM INSTITUTE | 5 ARTILLERIVEJ | COPENHAGEN | | | | DNK | R01AI093697 | Genome-wide association study of febrile seizures following measles, mumps, rubel | 000 | 2 | NIH | 6/7/2013 | $188,951 |
|
 | Issue Date FY: 2012 ( Subtotal = $113,400 ) |
| 2012 | 2012 | STATENS SERUM INSTITUTE | 5 ARTILLERIVEJ | COPENHAGEN | | | | DNK | R01AI093697 | Genome-wide association study of febrile seizures following measles, mumps, rubel | 000 | 1 | NIH | 5/31/2012 | $113,400 |
|
 | Issue Date FY: 2000 ( Subtotal = $644,289 ) |
| 2000 | 2000 | STATENS SERUM INSTITUTE | ORESTADS BOULEVARD 5 | COPENHAGEN | | | | DNK | R01CA069269 | DETERMINANTS OF THE SECULAR INCREASE IN NHL | 000 | 3 | NIH | 9/26/2000 | $644,289 |
|
 | Issue Date FY: 1999 ( Subtotal = $852,148 ) |
| 1999 | 1999 | STATENS SERUM INSTITUTE | ORESTADS BOULEVARD 5 | COPENHAGEN | | | | DNK | R01CA069269 | DETERMINANTS OF THE SECULAR INCREASE IN NHL | 000 | 2 | NIH | 9/29/1999 | $852,148 |
|
 | Issue Date FY: 1998 ( Subtotal = $362,000 ) |
| 1998 | 1998 | STATENS SERUM INSTITUTE | ORESTADS BOULEVARD 5 | COPENHAGEN | | | | DNK | R01CA069269 | DETERMINANTS OF THE SECULAR INCREASE IN NHL | 000 | 1 | NIH | 9/30/1998 | $362,000 |
|
|